- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Advanced Magnetics submits NDA for Combidex
Contrast agent supplier Advanced Magnetics has submitted a new drug application (NDA) to the Food and Drug Administration for Combidex, an MRI contrast agent. The company’s European marketing partner, Guerbet, has also submitted the European
Contrast agent supplier Advanced Magnetics has submitted a new drug application (NDA) to the Food and Drug Administration for Combidex, an MRI contrast agent. The companys European marketing partner, Guerbet, has also submitted the European equivalent of an NDA to the European Medicines Evaluations Agency. Combidex is Advanced Magnetics third product.
The companys U.S. NDA covers two indications: the diagnosis of lymph node disease and the detection, diagnosis, and evaluation of benign and malignant lesions of the liver and spleen. Advanced Magnetics hopes to receive priority review from the FDA for its Dec. 21 application, which would precipitate an action letter from the FDA six months from the application date rather than 12. Guerbet expects to launch Combidex in Europe in early 2001 under the trade name Sinerem.
The company hopes Combidex will help oncologists and radiologists to noninvasively stage metastatic cancer in lymph nodes. Advanced Magnetics plans to find a marketing partner for the agent, according to the Cambridge, MA-based firm.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
